益丰药房
(603939)
| 流通市值：297.40亿 | | | 总市值：297.40亿 |
| 流通股本：12.12亿 | | | 总股本：12.12亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 18,235,705,366.43 | 12,129,983,982.07 | 6,085,003,538.59 | 24,433,165,197.5 |
| 营业收入 | 18,235,705,366.43 | 12,129,983,982.07 | 6,085,003,538.59 | 24,433,165,197.5 |
| 二、营业总成本 | 16,277,422,543.41 | 10,737,842,732.39 | 5,386,162,931.81 | 22,129,134,049.16 |
| 营业成本 | 10,988,275,574.67 | 7,241,974,262.94 | 3,648,783,760.21 | 14,817,330,076.73 |
| 税金及附加 | 86,085,083.66 | 55,665,651.66 | 24,403,091.5 | 100,913,544.6 |
| 销售费用 | 4,251,051,723.38 | 2,825,257,795.3 | 1,368,576,218.51 | 5,854,321,676.31 |
| 管理费用 | 852,190,955.68 | 546,812,603.43 | 310,563,885.07 | 1,186,590,030.12 |
| 研发费用 | 17,342,029.13 | 11,553,736.13 | 5,853,144.25 | 27,916,037 |
| 财务费用 | 82,477,176.89 | 56,578,682.93 | 27,982,832.27 | 142,062,684.4 |
| 其中:利息费用 | 96,443,556.27 | 65,870,504.65 | 31,846,152.06 | 166,753,646.09 |
| 其中:利息收入 | 25,034,103.25 | 16,574,159.78 | 7,465,366.97 | 47,517,011.03 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 81,809,519.49 | 56,272,544.79 | 27,767,028.59 | 124,747,936.19 |
| 资产处置收益 | 33,425,845.75 | 23,206,570.32 | 11,356,506.77 | 68,481,322.52 |
| 资产减值损失(新) | -69,733,857.86 | -46,632,781.15 | -23,740,937.33 | -111,612,199.85 |
| 信用减值损失(新) | -2,990,644.4 | -3,403,083.41 | -1,225,635.45 | -36,992.73 |
| 其他收益 | 39,138,619.59 | 25,058,020.44 | 14,667,331.01 | 68,112,555.33 |
| 四、营业利润 | 2,039,932,305.59 | 1,446,642,520.67 | 727,664,900.37 | 2,453,723,769.8 |
| 加:营业外收入 | 16,191,714.37 | 15,420,402.26 | 2,133,912.01 | 37,754,018.54 |
| 减:营业外支出 | 30,371,279.26 | 20,293,528.88 | 6,159,025.24 | 35,082,935.93 |
| 五、利润总额 | 2,025,752,740.7 | 1,441,769,394.05 | 723,639,787.14 | 2,456,394,852.41 |
| 减:所得税费用 | 504,451,487.95 | 372,701,751.97 | 177,554,652.98 | 625,369,295.81 |
| 六、净利润 | 1,521,301,252.75 | 1,069,067,642.08 | 546,085,134.16 | 1,831,025,556.6 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,521,301,252.75 | 1,069,067,642.08 | 546,085,134.16 | 1,831,025,556.6 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,361,809,815.39 | 963,777,247.55 | 499,549,828.27 | 1,678,481,865.01 |
| 少数股东损益 | 159,491,437.36 | 105,290,394.53 | 46,535,305.89 | 152,543,691.59 |
| 扣除非经常损益后的净利润 | 1,287,565,182.53 | 910,491,618.38 | 493,053,446.12 | 1,529,833,263.88 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.12 | 0.79 | 0.41 | 1.38 |
| (二)稀释每股收益 | 1.1 | 0.78 | 0.4 | 1.36 |
| 八、其他综合收益 | - | - | - | 75,076,268.99 |
| 归属于母公司股东的其他综合收益 | - | - | - | 75,076,268.99 |
| 九、综合收益总额 | 1,521,301,252.75 | 1,069,067,642.08 | 546,085,134.16 | 1,906,101,825.59 |
| 归属于母公司股东的综合收益总额 | 1,361,809,815.39 | 963,777,247.55 | 499,549,828.27 | 1,753,558,134 |
| 归属于少数股东的综合收益总额 | 159,491,437.36 | 105,290,394.53 | 46,535,305.89 | 152,543,691.59 |
| 公告日期 | 2026-10-30 | 2026-08-28 | 2026-04-23 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |